Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate-risk clear cell kidney cancer.
Robert E ReiterAlexander HakanssonShinji OhtakePeter MurakiJames A ProudfoutYang LiuLisa WebberArkaitz IbarraVinnie Y T LiuElai DavicioniKarim ChamieAllan PantuckBrian ShuchPublished in: Cancer medicine (2022)
Transcriptomic recurrence scores improve risk prediction even when controlling for clinicopathologic factors. Utility may be best suited for intermediate-risk patients who have heterogeneous outcomes and further refinement for clinical utility is warranted.
Keyphrases
- end stage renal disease
- newly diagnosed
- free survival
- single cell
- chronic kidney disease
- ejection fraction
- clear cell
- rna seq
- prognostic factors
- papillary thyroid
- peritoneal dialysis
- squamous cell carcinoma
- metabolic syndrome
- skeletal muscle
- patient reported outcomes
- squamous cell
- insulin resistance
- glycemic control